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A recent genome-wide association study identiﬁed hepatocyte
nuclear factor 1-a (HNF1A) as a key regulator of fucosylation.
We hypothesized that loss-of-function HNF1A mutations causal
for maturity-onset diabetes of the young (MODY) would display
altered fucosylation of N-linked glycans on plasma proteins and
that glycan biomarkers could improve the efﬁciency of a diagno-
sis of HNF1A-MODY. In a pilot comparison of 33 subjects with
HNF1A-MODY and 41 subjects with type 2 diabetes, 15 of 29
glycan measurements differed between the two groups. The
DG9-glycan index, which is the ratio of fucosylated to nonfuco-
sylated triantennary glycans, provided optimum discrimination in
the pilot study and was examined further among additional sub-
jects with HNF1A-MODY (n = 188), glucokinase (GCK)-MODY
(n = 118), hepatocyte nuclear factor 4-a (HNF4A)-MODY (n =
40), type 1 diabetes (n = 98), type 2 diabetes (n = 167), and
nondiabetic controls (n = 98). The DG9-glycan index was
markedly lower in HNF1A-MODY than in controls or other di-
abetes subtypes, offered good discrimination between HNF1A-
MODY and both type 1 and type 2 diabetes (C statistic $0.90),
and enabled us to detect three previously undetected HNF1A
mutations in patients with diabetes. In conclusion, glycan proﬁles
are altered substantially in HNF1A-MODY, and the DG9-glycan
index has potential clinical value as a diagnostic biomarker of
HNF1A dysfunction. Diabetes 62:1329–1337, 2013
Genome-wide association studies are providingnovel insights into the genetic architecture andbiological basis of many diseases, but immedi-ate translation into clinical practice has been
limited. We recently performed a genome-wide association
study of the human plasma N-glycome and found evidence
of association involving common variants near the hepato-
cyte nuclear factor 1-a (HNF1A) gene; follow-up functional
experiments established HNF1A as a master regulator of
plasma protein fucosylation (1). Fucosylation, a speciﬁc
type of glycosylation, comprises the addition of fucose
residues to glycans. Here we evaluate the hypothesis that
mutations causing a more severe deﬁcit in HNF1A function
(resulting in the monogenic subtype of diabetes known as
HNF1A maturity-onset diabetes of the young [MODY;
HNF1A-MODY]) are associated with marked alterations of
plasma glycome composition, and we assess the value of
glycan proﬁles as a diagnostic biomarker for HNF1A-
MODY.
Most human proteins are posttranslationally modiﬁed by
the addition of complex oligosaccharide structures (gly-
cans) (2). Despite the impact on protein structure and
function, the clinical consequences of changes in the hu-
man glycome remain largely unexplored, primarily be-
cause reliable analytical techniques have been developed
only recently (3). In recent studies, HNF1A was shown to
promote both the de novo and salvage pathways for the
synthesis of guanosine diphosphate–fucose (1) and to
regulate fucosyltransferase VI (1,4). HNF1A thereby con-
trols the outer-arm (antennary) fucosylation of proteins
with N-linked glycans through effects on both the supply
of activated precursors and the incorporation of fucose
(1,4).
Mutations disrupting HNF1A are responsible for the most
common subtype of monogenic diabetes, HNF1A-MODY (5).
Like other forms of MODY, HNF1A-MODY is characterized
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by autosomal dominant inheritance and pancreatic b-cell
dysfunction. This typically leads to diabetes diagnosed in
the second to fourth decade of life in the absence of b-cell
autoimmunity and insulin resistance (5,6). In clinical prac-
tice, diagnostic differentiation between HNF1A-MODY and
other causes of early-onset diabetes (including type 1 and
type 2 diabetes and other forms of MODY) is complicated by
the overlap of phenotypic features. In most countries only
a minority of cases of HNF1A-MODY are referred for de-
ﬁnitive molecular testing (i.e., HNF1A sequencing), and
many patients with HNF1A-MODY are misdiagnosed with
type 1 or type 2 diabetes (7). Failures or delays in accurate
molecular diagnosis can have clinical repercussions be-
cause, unlike other forms of diabetes, the optimal treat-
ment for HNF1A-MODY is low-dose sulfonylureas (8).
Patients with undiagnosed HNF1A-MODY may spend
many years receiving inappropriate treatment (including
exogenous insulin) and experiencing suboptimal glycemic
control (9).
We aimed to test the hypothesis that inactivating
mutations in HNF1A, such as those found in HNF1A-
MODY, are associated with decreased antennary fucosy-
lation of circulating proteins and to evaluate the clinical
translational potential of measuring glycan proﬁles in
diabetes.
RESEARCH DESIGN AND METHODS
Subjects for initial and validation studies. Full details of the subjects are
available in Table 1 and the Supplementary Appendix. Subjects carrying
mutations in HNF1A (n = 221), glucokinase (GCK; n = 118), and hepatocyte
nuclear factor 4-a (HNF4A; n = 40) were recruited from ﬁve European cen-
ters. Subjects with MODY had an established heterozygous loss-of-function
mutation conﬁrmed by sequencing in a certiﬁed diagnostic center. All MODY
mutations were considered pathogenic if they met one or more of the fol-
lowing criteria: mentioned in previously published reports, presence of
a truncating mutation, cosegregation of the mutation with a MODY phenotype
within the family, and absence of the variant in normal chromosomes. In ad-
dition, we recruited 208 subjects with clinically labeled type 2 diabetes who
were diagnosed at an age younger than 45 years, 98 subjects with clinically
labeled type 1 diabetes, and 98 subjects who acted as nondiabetic controls.
Most samples were collected when the subject was in a fasting state, although
fasting status does not inﬂuence glycan levels (10).
Glycan release, labeling, and analysis. All samples were stored at 280°C
before analysis. Glycan release, labeling, and analysis using hydrophilic in-
teraction high-performance liquid chromatography and sialidase digestion was
performed as previously reported (11,12). Chromatograms from ﬂuorescently
labeled glycans were separated into 16 glycan groups (GP series) and 13
desialylated glycan groups (DG series), composing a total of 29 peaks (Sup-
plementary Table 1). The amounts of glycans present in each peak were
expressed as the percentage of the total plasma glycome. Glycan analysis was
performed in two centers: the National Institute for Bioprocessing Research
and Training (Dublin, Ireland) and the Glycobiology laboratory of Genos Ltd.
(Zagreb, Croatia). Both laboratories used the same columns and separation
conditions and previously have demonstrated reproducibility of analytic
results within and between laboratories (1,10).
Study design and analysis. All glycan traits were compared using Mann-
Whitney U tests in an initial study of 33 subjects with HNF1A-MODY and 41
subjects with type 2 diabetes. Based on these results (Supplementary Table 1),
the glycan ratio of DG9 to [DG8+DG9], hereafter referred to as the DG9-
glycan index, was chosen for further follow-up.
The validation study was performed using 188 subjects with HNF1A-MODY,
118 subjects with GCK-MODY, 40 subjects with HNF4A-MODY, 167 subjects
with type 2 diabetes, and 98 subjects with type 1 diabetes cases, plus 98 non-
diabetic controls. There was no overlap between the initial and validation
studies. We ﬁrst sought evidence for important covariates through analysis of
parameters including age, sex, BMI, HDL, triglycerides, sample origin, process-
ing laboratory, and sample type (plasma vs. serum). An adjusted model in-
corporated signiﬁcant covariates (age, BMI, sample origin, processing
laboratory) as well as those already known to affect speciﬁc glycan traits (sex).
An additional analysis was performed without covariates. The use of the DG9-
glycan index as a discriminator of diabetes subtypes was analyzed using receiver
operator characteristic (ROC) curves from which the C statistic was obtained. T
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Performance of the DG9-glycan index as a clinical tool was evaluated by cal-
culating sensitivity and speciﬁcity and other measures for the detection of
HNF1A-MODY at various thresholds. In particular, we estimated posttest di-
agnostic probabilities based on data from an etiological investigation of young
adults with diabetes from the U.K. that indicated pretest probabilities of 4% for
HNF1A-MODY in young-onset type 2 diabetes and 1% in type 1 diabetes (13).
The effect of the type of HNF1A mutation, the HNF1A isoform, and the
mutated functional domain of HNF1A on DG9-glycan index levels was
assessed. HNF1A mutations were classiﬁed as either protein-changing muta-
tions (missense mutations resulting in a change of amino acid) or truncating
mutations (which generate a premature stop codon). In addition, protein-
changing mutations were grouped as exons 1–6 [affecting isoforms HNF1A
(A), (B) and (C)], exon 7 [isoforms HNF1A (A) and (B)] and exons 8–10
[isoform HNF1A (A) only] (14,15). Protein-changing mutations also were
grouped according to the affected functional domain: dimerization, DNA
binding, or transactivation (14,15).
We also assessed evidence for pathogenicity of the HNF1A missense muta-
tions included in the validation study and examined whether the DG9-glycan
index correlated with other indicators of pathogenicity. These included cose-
gregation within families, functional characterization of mutant proteins, and in
silico prediction of the effect of the amino acid substitution on protein function.
HNF1A sequencing. In the subsequent case-ﬁnding study, we evaluated the
value of the DG9-glycan index as a screening test for identifying HNF1A-MODY
in a set of individuals with young-onset diabetes (diagnosed up to age 45
years) who had not previously been suspected of having an HNF1A mutation.
We tested subjects with a DG9-glycan index ,0.16 from the initial or valida-
tion studies with clinical labels of type 1 (n = 7) and type 2 diabetes (n = 41),
as well as subjects with diabetes of any type diagnosed up to age 45 years from
general population cohorts from Croatia (n = 6) and Scotland (n = 3) in whom
glycan proﬁles had been measured previously (1). The 10 exons of HNF1A
were ampliﬁed by PCR and bidirectional sequencing performed using M13
primers and a Big Dye Terminator Cycler Sequencing kit v1.1 (Applied Bio-
systems, Warrington, U.K.). Reactions were analyzed on an ABI 3730 capillary
sequencer (Applied Biosystems), and results were compared with the refer-
ence sequence (NM_000545.3) using Mutation Surveyor v3.97 (SoftGenetics,
Cambridge, U.K.). Mutation testing was undertaken in family members when
available to establish cosegregation. In silico analysis of missense mutations
was performed using the software program Condel (CONsensus DELeterious
score of missense single nucleotide polymorphisms) (16). Condel produces
a weighted average of scores from three computational tools [SIFT, Poly-
phen2, and Mutation-Assessor (17–19)] and classiﬁes missense single nucle-
otide polymorphisms as probably “deleterious” (i.e., pathogenic) or probably
“neutral” (i.e., benign).
All analyses were performed using SPSS version 17.0. The study was per-
formed in accordance with the latest version of the Declaration of Helsinki.
RESULTS
HNF1A-MODY andmeasures of antennary fucosylation.
In the initial study, we foundmarked differences in the plasma
glycome proﬁles between 33 subjects with HNF1A-MODY
and 41 subjects with early-onset type 2 diabetes. Fifteen of
29 glycan measures differed signiﬁcantly between the two
groups (P , 0.05) (Supplementary Table 1). Patterns were
consistent with the known effects of HNF1A on fucosyla-
tion (1), in that subjects with loss-of-function mutations in
HNF1A were characterized by an increase in the proportion
of glycans without antennary fucose.
Validation study. For the validation study, we focused on
DG9 and DG8 as measures of triantennary glycans with
and without antennary fucose, respectively (Fig. 1). There-
fore, the DG9-glycan index [DG9-to-(DG8+DG9) ratio] sum-
marizes the proportion of triantennary glycans that are
fucosylated. As well as consistency with the existing data on
HNF1A effects on fucosylation (1) and strong evidence from
the initial study (Supplementary Table 1), triantennary gly-
cans are not affected by the removal of ﬁbrinogen during
coagulation (G. Lauc, unpublished observations), allowing
our validation studies to include both serum and plasma
samples.
The distributions of DG9-glycan index measures for the
709 individuals in the validation study differed signiﬁcantly
between the subject groups (Fig. 2; Supplementary Table
2). Median (interquartile range) DG9-glycan index levels
were substantially lower in subjects with HNF1A-MODY
[0.09 (0.06–0.13)] than in those with young-onset type
2 diabetes [0.25 (0.18–0.33); P = 1 3 10239 vs. HNF1A-
MODY], type 1 diabetes [0.28 (0.20–0.34);, P = 13 10234 vs.
HNF1A-MODY], or GCK-MODY [0.25 (0.18–0.31); P = 5 3
10232 vs. HNF1A-MODY]. DG9-glycan index levels in
subjects with HNF1A-MODY were also lower when com-
pared with controls [0.24 (0.19–0.29); P = 1 3 10232 vs.
HNF1A-MODY] and against all other diabetic patients
combined [0.25 (0.18–0.31); P = 5 3 10255 vs. HNF1A-
MODY]. Consistent with evidence that HNF4A also regu-
lates fucosylation (1), cases of HNF4A-MODY showed
DG9-glycan index levels between those in HNF1A-MODY
and other forms of diabetes [0.18 (0.09–0.24); P = 2 3 1027
vs. HNF1A-MODY].
Adjustment for signiﬁcant covariates had no appreciable
impact on the magnitude or signiﬁcance of differences in
DG9-glycan index values between groups (Supplementary
Table 2).
Receiver operating characteristic (ROC) curve analyses.
To test whether glycan proﬁling had potential as a clinically
FIG. 1. A: Structural symbols for N-glycans, their linkages, and the abbreviations used. The Oxford nomenclature has been used to represent
N-linked glycan composition and structure (20). B: Representations of the structures of the major glycans in DG8 and DG9 high-performance liquid
chromatography peaks. Both are triantennary glycans. The only difference is the presence of a terminal fucose residue ( ) attached to one of the
antennae of the glycans in DG9.
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valid screening test, C statistic measures of discriminative
accuracy were derived from ROC curve analyses (Fig. 3;
Supplementary Table 3). The C statistic was 0.94 forHNF1A-
MODY against type 1 diabetes and 0.91 for HNF1A-MODY
against early-onset type 2 diabetes. Similar discrimination
was observed for the comparison of HNF1A-MODY and
GCK-MODY (C statistic 0.90), but the DG9-glycan index
performed less well in differentiating HNF4A-MODY and
HNF1A-MODY (C statistic 0.76). These measures were not
affected by sample type (serum vs. plasma; Supplementary
Table 3).
We have reported previously that high-sensitivity C-
reactive protein (hs-CRP) is a sensitive and speciﬁc bio-
marker for HNF1A-MODY (21,22). In the validation
dataset, the ability of the DG9-glycan index to discrimi-
nate between HNF1A-MODY and type 2 diabetes was
comparable with hs-CRP (C statistic 0.91 and 0.94, re-
spectively). However, the DG9-glycan index provided
superior discrimination of HNF1A-MODY from type 1
diabetes compared with hs-CRP (C statistic 0.94 vs. 0.83
for hs-CRP).
Other glycan measures. As described earlier, our pri-
mary validation analyses focused on the DG9-glycan index.
However, the availability of full glycome proﬁles for the
validation samples allowed us to explore the relative per-
formance of other measures highlighted in the initial study.
Other glycan ratios, such as DG7 to (DG5+DG6), repre-
senting the proportion of biantennary fucosylated glycans,
offered good discrimination between diabetes subtypes
(Supplementary Table 3). The DG7-to-(DG5+DG6) ratio
provided near perfect discrimination between HNF1A-
MODY and type 2 diabetes (C statistic .0.99) in plasma
samples, but it performed less well in analyses of serum
samples (C statistic 0.78).
Correlates of the DG9-glycan index within the
HNF1A-MODY group. Eighteen subjects within the
HNF1A-MODY group did not have diabetes when glycans
were sampled. DG9-glycan index levels were not different
in the patients with HNF1A-MODY with and without di-
abetes (P = 0.45). This further conﬁrms that these changes
in antennary fucosylation are speciﬁc to loss-of-function
HNF1A mutations and are unrelated to dysglycemia. DG9-
glycan index levels were not correlated with the age at
diabetes diagnosis (P = 0.38).
Analysis by mutation type showed median DG9-glycan
index was lower in subjects with HNF1A-MODY with
protein-changing mutations than those with truncating
mutations (0.08 vs. 0.10; P = 0.003) (Table 2). This differ-
ence in DG9-glycan index levels did not remain signiﬁcant
when analysis was restricted to one individual per family
(the proband), a maneuver that renders the observations
independent at the expense of a reduced sample size (P =
0.18). Analysis by functional domain indicated lower me-
dian DG9-glycan index in subjects with HNF1A-MODY
with missense mutations affecting the dimerization/DNA-
binding domains compared with those with missense
mutations in the transactivation domain (0.08 vs. 0.13; P =
0.04). The latter relationship was consistent whether we
considered all subjects with HNF1A-MODY or only the
probands (P = 0.04 and 0.002, respectively). The HNF1A
isoform affected had no effect on DG9-glycan index levels
(P = 0.30).
We also examined whether the DG9-glycan index could be
used as a marker of HNF1A function to provide additional
FIG. 2. Dot histograms illustrating the DG9-glycan index in different diabetes subtypes and nondiabetic control subjects. Subjects are represented
by the following symbols:● =HNF1A-MODY;○ = type 2 diabetes;▲ = type 1 diabetes;△ =GCK-MODY (GCK-MODY);■ =HNF4A-MODY (HNF4A-
MODY); □ = nondiabetic controls. P values are calculated by Mann-Whitney U tests in comparison with subjects with HNF1A-MODY. The median
value of the DG9-glycan index for each diabetes subtype is highlighted adjacent to a black dashed line.
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evidence regarding pathogenicity. All missense HNF1A
mutations in this study were classiﬁed as probably “delete-
rious” (i.e., pathogenic) or probably “neutral” (i.e., benign)
using the software program Condel. Four missense HNF1A
mutations (in ﬁve subjects) had Condel scores within the
benign range: c.92G.A p.Gly31Asp, c.142G.A p.Glu48Lys,
c.871C.A p.Pro291Thr, and c.1816G.A p.Gly606Ser. Family
data for these mutations were generally less supportive of
pathogenicity because of incomplete cosegregation, later
age at diagnosis of diabetes, or unavailability of family
FIG. 3. ROC curves illustrating the performance of the DG9-glycan index to discriminateHNF1A-MODY and type 2 diabetes (A);HNF1A-MODY and
type 1 diabetes (B);HNF1A-MODY and other diabetes subtypes combined (C);HNF1A-MODY and GCK-induced MODY (GCK-MODY) (D);HNF1A-
MODY and HNF4A-MODY (E); and HNF1A-MODY and nondiabetic control subjects (F).
TABLE 2
DG9-glycan index levels in subjects with HNF1A-MODY according to type and position of HNF1A mutation
Subjects with
HNF1A-MODY (n)
DG9-glycan
index* P
Unrelated subjects with
HNF1A-MODY (n)
DG9-glycan
index* P
Truncating mutations 83 0.10 (0.07–0.21) 0.003 39 0.10 (0.07–0.14) 0.180Protein-changing mutations 105 0.08 (0.05–0.21) 44 0.08 (0.05–0.14)
Classiﬁed by isoform affected
Exons 1–6 [isoforms HNF1A(A),
(B) and (C)] 93 0.08 (0.05–0.21)
0.300
42 0.08 (0.05–0.11)
N/AExon 7 [isoforms HNF1A(A)and (B)] 11 0.09 (0.05–0.18) 1 0.13
Exons 8–10 [isoform
HNF1A(A) only] 1 0.21 1 0.21
Classiﬁed by affected functional domain
Dimerization/DNA-binding domains† 62 0.08 (0.05–0.17) 0.043 26 0.08 (0.05–0.11) 0.002
Transactivation domain‡ 17 0.13 (0.08–0.25) 4 0.21 (0.17–0.24)
P values calculated using Mann-Whitney U and Kruskal-Wallis tests. The Mann-Whitney U test was used to test truncating versus protein-
changing mutations and dimerization/DNA-binding versus transactivation domains, while the Kruskal-Wallis test was used to compare the
isoforms. *Data expressed as median (25th–75th centiles). †Dimerization domain (amino acids 1–32) and DNA-binding domain (amino acids
91–281). ‡Transactivation domain (amino acids 282–631).
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members for testing. The median (interquartile range) DG9-
glycan index levels in these ﬁve subjects were signiﬁcantly
higher compared with the remainder of the group with
HNF1A missense mutations [0.16 (0.11–0.21) vs. 0.08 (0.05–
0.11); P = 0.01].
Clinical potential of the DG9-glycan index. To examine
the performance of the DG9-glycan index as a diagnostic
screen in clinical practice, we based analyses on U.K. data
showing that subjects with unrecognized HNF1A-MODY
account for approximately 4% of young-onset type 2 di-
abetes (diagnosed #45 years) and 1% of type 1 diabetes
(13). On the basis of the validation study, we estimate that
a diagnostic threshold for the DG9-glycan index of 0.16
confers 88% sensitivity and 81% speciﬁcity for the dis-
crimination of HNF1A-MODY from young-onset type 2
diabetes and 88% sensitivity and 88% speciﬁcity for
equivalent comparisons with type 1 diabetes. In contrast,
an age younger than 25 years at diagnosis of diabetes,
which is the most widely used diagnostic feature for
MODY, has lower sensitivity (64%) but higher speciﬁcity
(99%) for the discrimination of HNF1A-MODY from young-
onset type 2 diabetes. We calculate that a patient with di-
abetes who is diagnosed before or at age 45 years, who has
an existing clinical label of type 2 diabetes, and who is
found to have a DG9-glycan index #0.16 has a posttest
probability of harboring an underlying HNF1A mutation of
16%, whereas the same patient with a DG9-glycan index
.0.16 has a 1% posttest probability of having unrecognized
HNF1A-MODY.
HNF1A-MODY case-ﬁnding in diabetic subjects. The
results of the validation study indicated that a diagnostic
threshold of 0.16 for the DG9-glycan index provided opti-
mum discrimination from both type 1 and type 2 diabetes.
HNF1A sequencing was performed in 57 subjects with
young-onset diabetes and who were clinically labeled as
having type 1 or type 2 diabetes, all of whom had a DG9-
glycan index #0.16. These subjects were either from the
initial or validation studies or recruited from general
population cohorts in Croatia and Scotland. Three of these
57 individuals were found to have HNF1A mutations.
The ﬁrst proband (Supplementary Fig. 1A) was hetero-
zygous for the missense mutation c.608G.A p.Arg203His
in exon 3, which previously has been shown to be causal
for MODY (23). The phenotype is consistent with HNF1A-
MODY with a two-generation history of young-adult onset
diabetes, and, although treated with insulin and labeled
with type 1 diabetes since diagnosis at age 31, this patient
was found to have residual endogenous insulin secretion
17 years after diagnosis (C-peptide, 0.27 nmol/L). Two
sisters with insulin-treated diabetes also carry the
Arg203His mutation. One sister has stopped basal-bolus
insulin successfully after the diagnosis of MODY and her
diabetes is well controlled with gliclazide; the proband is
considering a similar change in therapy. In the second
proband (Supplementary Fig. 1B), a novel missense vari-
ant c.139G.C, p.Gly47Arg was identiﬁed in exon 1. This
subject, now aged 53 years, was diagnosed with presumed
type 2 diabetes at age 37. Her mother, diagnosed with type
2 diabetes at age 70, also carries the mutation. A normo-
glycemic son, currently 29 years old, does not carry the
mutation. In the third proband (Supplementary Fig. 1C),
a novel missense mutation c.751G.A, p.Ala251Thr was
found in exon 4. This proband was diagnosed with di-
abetes at age 43 and is being managed with sulfonylurea
(and metformin) therapy 25 years later. Sensitivity to sul-
fonylureas and maintenance of diabetes control for many
years while taking these agents is typical of subjects with
HNF1A-MODY. The proband’s mother and a sister had
diabetes in old age.
To assess pathogenicity for the two novel variants
(Gly47Arg and Ala251Thr), we ﬁrst established that both
variants were absent from 400 normal chromosomes and
the October 2011 release of the consensus calls for the
1000 Genomes Project (24). The Ala251Thr variant is not
reported in the National Heart, Lung, and Blood Institute’s
Exome Sequencing Project (N = 6503; accessed June 2012
via the Exome Variant Server) (25), whereas the Gly47Arg
variant is reported in a single European American in-
dividual. The phenotypic characteristics of this subject are
not declared: because the Exome Sequencing Project
includes cases of metabolic and cardiovascular disease,
this ﬁnding does not exclude a pathogenic role for this
variant. Second, we assessed whether the mutated resi-
dues were conserved across species. Both Gly47 and
Ala251 are highly conserved: Ala251 is conserved in eight
of the nine orthologs tested, including frog, chicken, and
six mammalian orthologs, whereas Gly47 is conserved in
seven of the nine orthologs tested, including Xenopus,
chicken, and ﬁve mammalian orthologs. In silico pre-
diction software was more ambiguous: Condel predicted
that the variant Gly47Arg is “neutral” and that Ala251Thr is
“deleterious.” Overall, we regard the clinical and bio-
informatic data for these two variants as supportive, but
not conclusive, evidence in favor of pathogenicity. The low
DG9-glycan index levels associated with Gly47Arg and
Ala251Thr (0.12 and 0.15, respectively) provide additional
support for pathogenicity. Deﬁnitive evidence of a causal
role would require more extensive clinical (including the
detection of these mutations in additional MODY families)
and functional studies.
DISCUSSION
The study conﬁrms the hypothesis that the glycan proﬁle
of plasma proteins is altered substantially in those with
HNF1A mutations. We also demonstrated that these dif-
ferences could be exploited as biomarkers in diabetes
diagnostics and showed that the DG9-glycan index can
discriminate HNF1A-MODY from both type 1 and type 2
diabetes.
Recent efforts to improve diagnostic performance by
identifying biochemical markers speciﬁc for MODY sub-
types have met with varying success (21,26–32). We re-
cently demonstrated that individuals with HNF1A-MODY
have low levels of C-reactive protein and that hs-CRP
assays can discriminate well between HNF1A-MODY and
both type 2 diabetes and HNF4A-MODY (21,22,33). How-
ever, hs-CRP does not provide good discrimination be-
tween HNF1A-MODY and type 1 diabetes. Furthermore,
hs-CRP is an acute inﬂammatory marker, and diagnostic
discrimination can be disturbed by intercurrent infection.
Potential advantages of the DG9-glycan index in this con-
text include stability over time (10) and differentiation of
HNF1A-MODY from both common types of diabetes. Al-
though there is some indication that glycan proﬁles are
affected by acute inﬂammation (34), all four subjects with
HNF1A-MODY and elevated levels of hs-CRP (.10 mg/L)
in the current study had DG9-glycan indices below 0.16.
This suggests that the DG9-glycan index is less prone to
spurious elevation from intercurrent infection than hs-
CRP, although this will require conﬁrmation in larger
numbers.
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The ability to discriminate between HNF1A-MODY and
type 1 diabetes in subjects with recently diagnosed di-
abetes is particularly important because diagnostic mis-
classiﬁcation can lead to the unwarranted decision to
recommend lifelong therapy with exogenous insulin. De-
tectable C-peptide can indicate HNF1A-MODY rather than
type 1 diabetes of long duration, but it is not helpful close
to a diagnosis of diabetes because a substantial proportion
of type 1 diabetes patients retain some production of en-
dogenous insulin (35). In this study we did not explicitly
examine type 1 diabetes during the honeymoon period;
however, glycan proﬁles are stable within an individual
over time, which suggests these measures will continue to
provide useful discriminative power from type 1 diabetes
close to diagnosis (36). In principle, therefore, the addition
of the DG9-glycan index to existing biomarkers such as hs-
CRP (21), 1,5-anhydroglucitol (29), pancreatic autoanti-
bodies (37), and C-peptide (13,35) should improve the
capacity for clinical discrimination of all major diabetes
subtypes.
With respect to clinical utility, our study showed that it
was possible to identify subjects with HNF1A mutations
using the DG9-glycan index. Given the high sensitivity and
speciﬁcity of the DG9-glycan index, the proportion of
cases found was lower than might have been expected (3
of 57; 5%). There are several possible explanations. The
ﬁrst is that the estimate of discriminatory power based on
the C statistics calculated during the validation study is
inﬂated, perhaps because of overﬁtting (38). An alternative
explanation is that discovery of novel cases of HNF1A-
MODY might have been compromised in our study sam-
ples by the extent of existing clinical investigation (e.g.,
approximately 30% of the Oxford samples had undergone
HNF1A sequencing). Another intriguing possibility is that
a small proportion of individuals in large, population-based
cohorts have low DG9-glycan index levels due to low-
frequency alleles in genes other than HNF1A, which play
an important role in protein fucosylation, such as those
encoding the fucosyltransferases FUT6 and other genes
(1). Further validation of the DG9-glycan index in un-
selected groups of subjects with young-onset diabetes will
be required to assess performance in a more typical clin-
ical scenario in which extensive prior screening for
monogenic disease has not been undertaken.
The use of the DG9-glycan index in clinical practice
currently is restricted by the cost and limited availability of
accurate glycan proﬁling. Clinical translation is, therefore,
dependent on the implementation of a focused assay for
speciﬁc glycan moieties rather than the global chromato-
graphic proﬁling used in this study. The DG9-glycan index
seems to be the most promising candidate from this study,
although the validation study suggests that other measures
[such as the DG7-to-(DG5+DG6) ratio] might have superior
performance when plasma (rather than serum) samples
are available—a ﬁnding that requires further conﬁrmation.
There is some evidence for a genotype-phenotype re-
lationship of glycan levels within subjects with HNF1A-
MODY, including that DG9-glycan index levels are lower in
those with protein-changing rather than truncating HNF1A
mutations. We reported a similar relationship in our stud-
ies of hs-CRP; in this case, restricting the analysis to in-
dependent probands did not abolish the signiﬁcance (22).
These observations would be consistent with a dominant-
negative effect, which has been reported for some HNF1A
mutations (39,40). Missense mutations disrupting the DNA-
binding and dimerization domains have signiﬁcantly lower
DG9-glycan index levels than those affecting the trans-
activation domain. This indicates a more severe functional
outcome of HNF1A mutations that disturb DNA binding.
This ﬁnding is consistent with previous reports of decreased
age at diabetes diagnosis in subjects with HNF1A-MODY
who have missense mutations within the DNA-binding/
dimerization domains compared with those in the trans-
activation domain (14,15).
This study primarily aimed to deﬁne the role of glycans
as a potential adjunct in the diagnosis of HNF1A-MODY
and, in particular, the capacity of this measure to improve
the targeting of (relatively expensive and therefore re-
stricted) diagnostic sequencing. However, anticipated
reductions in the cost of diagnostic sequencing are likely
to encourage more liberal access to HNF1A sequencing,
including many individuals with a relatively low risk of
MODY. In this setting, the problem shifts toward correctly
interpreting the clinical signiﬁcance of the many novel
HNF1A variants that will be uncovered, and we provide
preliminary evidence that biomarkers of HNF1A, such as
the DG9-glycan index, may prove useful in this context.
In summary, the use of the DG9-glycan index both as
a biomarker for HNF1A-MODY and as a promising bio-
chemical measure of HNF1A function represents a com-
pelling example of the potential for rapid clinical
translation of a genetic discovery originating from a ge-
nome-wide association analysis.
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